Project Grant R01HL180235
- Federal Project Grant Award Summary Emory University received a $156,080 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded March 13, 2026, with completion targeted for September 11, 2027. The grant supports research investigating HEG1 (Heart of Glass 1) as a regulator of hypertension and atherosclerosis, addressing a critical gap in understanding the molecular and cellular mechanisms underlying these...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $252,000 project grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through August 31, 2027. This ancillary study investigates the relationship between menopausal hormone therapy, gut microbiome composition, and estrogen-related health outcomes in women living with HIV (WWH). The research leverages an...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham $223,438 on September 4, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a clinical research study examining hypertension incidence in people with HIV initiating antiretroviral therapy (ART). The project, scheduled for completion by August 31, 2027, will assess blood pressure outcomes in ART-naïve individuals starting either...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $798,698 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 10, 2025, with completion targeted for June 30, 2030. The project, titled "Cardiac Function and Proteomic Biomarkers in Individuals with Perinatal HIV Infection or Exposure," aims to comprehensively characterize cardiac dysfunction...
- Federal Project Grant Award Summary Emory University's Office of Sponsored Programs received a $391,211 Project Grant from the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 1, 2026, through May 31, 2029. The award funds research investigating alloimmune responses to hemophilia therapeutics, specifically examining the mechanisms underlying anti-drug antibody (inhibitor) development against coagulation factor...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Florida Division of Sponsored Research a Project Grant of $782,085 (awarded June 25, 2026; completion February 28, 2031) under the Cardiovascular Diseases Research program (CFDA 93.837). This project will deliver research services focused on identifying actionable multilevel intervention strategies to improve cardiovascular health among people with HIV (PWH). The research will employ...
- Federal Project Grant Award Summary Emory University received a $584,575 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 3, 2025, with completion targeted for May 31, 2030. The award funds development and validation of correction equations to enhance the accuracy of infrared medical devices, specifically pulse oximeters and temporal thermometers used in intensive care unit (ICU)...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Emory University $110,635 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025, for a project grant extending through August 31, 2027. The award funds research investigating the role of blood rheology and transfusion interventions in microvascular thrombosis during sepsis. The project will utilize microfluidics assays to characterize how red blood cell (RBC) aggregation and...
- Federal Project Grant Award Summary Emory University received a $162,080 Project Grant award dated March 13, 2026, from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to support research defining the function of C/EBP-beta and its downstream target PSMB9 in atherosclerosis. The research addresses cardiovascular disease, which remains the leading cause of death worldwide despite advances in treatment. The project will...
- Federal Grant Award Summary Emory University's Office of Sponsored Programs received a $232,498 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 15, 2025, with a completion date of July 31, 2027. The grant supports the development of a predictive risk model for Fontan failure—a serious complication affecting pediatric and adult patients with rare single ventricle heart defects who have...
Emory University received a $783,830 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2026, with completion scheduled for March 31, 2030. The award funds the HIV and Endothelial Function in Women of Reproductive Age (HEART) study, a prospective cohort investigation conducted at Atlanta and Miami sites that will enroll 400 participants to longitudinally examine vascular endothelial function, ovarian hormones, inflammatory response, and hypertension incidence in women of reproductive age with and without HIV. The primary deliverables include longitudinal clinical and laboratory data characterizing the mechanisms underlying hypertension development in women living with HIV, with particular attention to the roles of reproductive aging, immune activation, and estradiol levels in vascular dysfunction. By leveraging the existing NIH-funded Study of Treatment and Reproductive Outcomes in Women (STAR) cohort, the study will generate evidence to identify reproductive-aged women living with HIV at highest cardiovascular disease risk and inform prevention strategies in the modern antiretroviral treatment era. The research addresses a critical gap in understanding why women living with HIV experience elevated cardiovascular disease risk that is more pronounced in younger populations.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $783.8k | 7/16/26 |